The cancer immunotherapy sector sees emerging approaches and substantial funding rounds aiming to tackle solid tumors. Dispatch Bio, a startup backed by $216 million from investors including the Parker Institute and Arch Venture Partners, unveiled a two-component approach combining a viral antigen delivery platform with engineered immune effector cells to generate ‘universal’ solid tumor treatments. Concurrently, advancements in engineered IL-18 variants and CAR-T in vivo therapies spotlight innovative modalities under development. Funding activity in this space reflects sustained investor interest despite challenging market conditions.